Free Flow Medical is developing a next generation medical device technology to treat patients with emphysema, an advanced form of chronic obstructive disease (COPD) that severely limits quality of life, presents the patient with ongoing severe breathlessness and eventual mortality. COPD is the third leading cause of death in the US behind cancer and heart disease. Almost 15.7 million US adults in 2014 have been diagnosed with COPD according Centers for Disease Control and Prevention.
Free Flow Medical’s founding team is led by inventor/entrepreneur, Mark Mathis. In addition to being involved in a variety of areas within the medical device field since the 1980’s, and holding over 100 patents, Mark founded and built PneumRx Inc, where he invented the nitinol coil implant technology that is still the only successful treatment for homogeneous emphysema patients. In early 2015, PneumRx was acquired by BTG for $475M. BTG was acquired by Boston Scientific.
Free Flow Medical has filed significant patents and developed a next generation device that will provide benefit for both heterogeneous and homogeneous COPD. The company is partnered with the top clinical experts in the US and Europe who have led and enrolled the majority of patients in all major trials conducted to date in this field. The company was awarded ISO certification and CE Mark approval of it’s first product in late 2020.
Company’s Keywords:
pulmonology
<7
<
<2017
Your request has been submitted successfully.
Own or work here?